{"entity":{"id":"nct07535463","kind":"trial","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of ivonescimab in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07535463 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 53 participants, started 2026-04-10 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab; Stereotactic Radiosurgery. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: identify the Recommended Phase 2 Dose (RPD2); intracranial progression-free survival (iPFS),. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed non-small cell lung cancer, including squamous and non-squamous histologies\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07535463","url":"https://clinicaltrials.gov/study/NCT07535463"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","bispecific-antibody","checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["ivonescimab"],"companies":["summit-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07535463","phase":"1/2","setting":"Safety and Efficacy of Ivonescimab and Chemotherapy Plus Stereotactic Radiosurgery (SRS) in the Treatment of Non-Small Cell Lung Cancer Brain Metastases","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":53,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07535463/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}